$EQ 8-K SEC Filings

Filed On	Filing
26 Oct 2026	8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027
05 Oct 2026	8-K: Other Events On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification...
13 Aug 2026	8-K: Results of Operations and Financial Condition
29 May 2026	8-K: Submission of Matters to a Vote of Security Holders
13 May 2026	8-K: Results of Operations and Financial Condition
25 Mar 2026	8-K: Results of Operations and Financial Condition
13 Mar 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
13 Nov 2025	8-K: Results of Operations and Financial Condition
06 Oct 2025	8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation +1 more
19 Sep 2025	8-K: Other Events
04 Sep 2025	8-K: Other Events
11 Aug 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
04 Aug 2025	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
13 Jun 2025	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
22 May 2025	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
24 Apr 2025	8-K: Results of Operations and Financial Condition
27 Mar 2025	8-K: Results of Operations and Financial Condition
06 Feb 2025	8-K: Other Events
13 Dec 2024	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
12 Dec 2024	8-K: Departure/Election of Directors or Officers; Compensation

Comments